secwatch.observer — SEC 8-K summary
======================================

Issuer:     INVO Fertility, Inc. (IVF)
CIK:        0001417926
Form:       8-K
Filed at:   2024-04-16T23:59:59+00:00
Accession:  0001493152-24-014846
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

INVO Bioscience reports FY2023 revenue $3.02M (+267% YoY); net loss narrows to $8.0M
--------------------------------------------------------------------------------

- FY2023 revenue $3,020,575, up 267% from $822,196; clinic revenue increased 366% to $2,862,574.
- FY2023 net loss $(8.0)M vs $(10.9)M; adjusted EBITDA $(5.1)M vs $(8.4)M.
- Q4 2023 revenue $1.38M, up 397% YoY; operating expenses decreased to $2.9M.
- Merger: INVO to acquire NAYA in all-stock; NAYA shareholders get 7.3333 INVO shares per share; conditions include shareholder approval and $2M+ PIPE.
- NAYA has provided ~$805,000 in financing to date; management expects to file updated proxy S-4 soon.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1417926/000149315224014846/0001493152-24-014846-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1417926/000149315224014846/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-014846

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer